With the first-ever oral drug of its kind, risdiplam is sure to open new doors for the SMA community. This especially holds true for those who have spinal fusions and are unable to get Spinraza administered as a result.
Would you like to know more about risdiplam? If so, please send us your questions so that we can try to help you.
All excellent questions, Tracy! I’m curious to know these answers, too.
With the drug currently under review, the FDA limits the amount of information the pharmaceutical company is allowed to release. Right now, the only concrete information we know is that Roche/Genentech has received priority review status, and this priority review status gives a good indication of the success of the clinical trials. But until the FDA actually grants Roche/Genentech approval for risdiplam, it’s probably more speculation than fact.
When more information becomes available, we will be sure to inform our forum members as soon as possible!
SMA News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.